139 related articles for article (PubMed ID: 15923278)
1. Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies.
Verma A; Kilicaslan F; Martin DO; Minor S; Starling R; Marrouche NF; Almahammed S; Wazni OM; Duggal S; Zuzek R; Yamaji H; Cummings J; Chung MK; Tchou PJ; Natale A
Heart; 2006 Feb; 92(2):190-5. PubMed ID: 15923278
[TBL] [Abstract][Full Text] [Related]
2. Prognostic role of high-sensitivity C-reactive protein and B-type natriuretic peptide in implantable cardioverter-defibrillator patients.
Theuns DA; Smith T; Szili-Torok T; Muskens-Heemskerk A; Janse P; Jordaens L
Pacing Clin Electrophysiol; 2012 Mar; 35(3):275-82. PubMed ID: 22150371
[TBL] [Abstract][Full Text] [Related]
3. Comparison of N-terminal pro-brain natriuretic peptide versus electrophysiologic study for predicting future outcomes in patients with an implantable cardioverter defibrillator after myocardial infarction.
Yu H; Oswald H; Gardiwal A; Lissel C; Klein G
Am J Cardiol; 2007 Aug; 100(4):635-9. PubMed ID: 17697820
[TBL] [Abstract][Full Text] [Related]
4. Predictors of appropriate implantable cardioverter defibrillator (ICD) therapy in primary prevention patients with ischemic and nonischemic cardiomyopathy.
Verma A; Sarak B; Kaplan AJ; Oosthuizen R; Beardsall M; Wulffhart Z; Higenbottam J; Khaykin Y
Pacing Clin Electrophysiol; 2010 Mar; 33(3):320-9. PubMed ID: 19796352
[TBL] [Abstract][Full Text] [Related]
5. Role of proinflammatory markers and NT-proBNP in patients with an implantable cardioverter-defibrillator and an electrical storm.
Streitner F; Kuschyk J; Veltmann C; Ratay D; Schoene N; Streitner I; Brueckmann M; Schumacher B; Borggrefe M; Wolpert C
Cytokine; 2009 Sep; 47(3):166-72. PubMed ID: 19604708
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study.
Bellocci F; Biasucci LM; Gensini GF; Padeletti L; Raviele A; Santini M; Giubilato G; Landolina M; Biondi-Zoccai G; Raciti G; Sassara M; Castro A; Kheir A; Crea F
J Cardiovasc Med (Hagerstown); 2007 Apr; 8(4):293-9. PubMed ID: 17413310
[TBL] [Abstract][Full Text] [Related]
7. Renal insufficiency predicts the time to first appropriate defibrillator shock.
Hreybe H; Ezzeddine R; Bedi M; Barrington W; Bazaz R; Ganz LI; Jain S; Ngwu O; London B; Saba S
Am Heart J; 2006 Apr; 151(4):852-6. PubMed ID: 16569548
[TBL] [Abstract][Full Text] [Related]
8. A comparison of outcomes for patients receiving implantable cardioverter defibrillators for primary vs secondary-prevention.
Giedrimas A; Giedrimiene D; Guertin D; White CM; Clyne CA; Kluger J
Conn Med; 2008; 72(6):329-33. PubMed ID: 18610705
[TBL] [Abstract][Full Text] [Related]
9. Increased N-terminal-pro-B-type natriuretic peptide levels in patients with appropriate implantable defibrillator therapies.
Arnaldo FJ; Anatoliotakis N; Palacio C; Nabert DR; Hsu SS
Heart Lung; 2009; 38(1):10-6. PubMed ID: 19150526
[TBL] [Abstract][Full Text] [Related]
10. Elevated B-type natriuretic peptide is associated with increased in-hospital mortality or cardiac arrest in patients undergoing implantable cardioverter-defibrillator implantation.
Wei S; Loyo-Berríos NI; Haigney MC; Cheng H; Pinnow EE; Mitchell KR; Beachy JH; Woodward AM; Wang Y; Curtis JP; Marinac-Dabic D
Circ Cardiovasc Qual Outcomes; 2011 May; 4(3):346-54. PubMed ID: 21487093
[TBL] [Abstract][Full Text] [Related]
11. A clinical risk score to predict the time to first appropriate device therapy in recipients of implantable cardioverter defibrillators.
Hreybe H; Saba S
Pacing Clin Electrophysiol; 2007 Mar; 30(3):385-9. PubMed ID: 17367358
[TBL] [Abstract][Full Text] [Related]
12. Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction.
Blangy H; Sadoul N; Dousset B; Radauceanu A; Fay R; Aliot E; Zannad F
Europace; 2007 Sep; 9(9):724-9. PubMed ID: 17526509
[TBL] [Abstract][Full Text] [Related]
13. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial.
Sweeney MO; Wathen MS; Volosin K; Abdalla I; DeGroot PJ; Otterness MF; Stark AJ
Circulation; 2005 Jun; 111(22):2898-905. PubMed ID: 15927965
[TBL] [Abstract][Full Text] [Related]
14. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms of the adrenergic system and implantable cardioverter-defibrillator therapies in patients with heart failure.
Chemello D; Rohde LE; Santos KG; Silvello D; Goldraich L; Pimentel M; Rosa PR; Zimerman L; Clausell N
Europace; 2010 May; 12(5):686-91. PubMed ID: 20185488
[TBL] [Abstract][Full Text] [Related]
16. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study.
Schnabel R; Lubos E; Rupprecht HJ; Espinola-Klein C; Bickel C; Lackner KJ; Cambien F; Tiret L; Münzel T; Blankenberg S
J Am Coll Cardiol; 2006 Feb; 47(3):552-8. PubMed ID: 16458135
[TBL] [Abstract][Full Text] [Related]
17. Circulating heart-type fatty acid binding protein levels predict the occurrence of appropriate shocks and cardiac death in patients with implantable cardioverter-defibrillators.
Daidoji H; Arimoto T; Nitobe J; Tamura H; Kutsuzawa D; Ishigaki D; Ishino M; Takahashi H; Shishido T; Miyashita T; Miyamoto T; Watanabe T; Kubota I
J Card Fail; 2012 Jul; 18(7):556-63. PubMed ID: 22748489
[TBL] [Abstract][Full Text] [Related]
18. Rates and predictors of appropriate implantable cardioverter-defibrillator therapy delivery: results from the EVADEF cohort study.
Otmani A; Trinquart L; Marijon E; Lavergne T; Waintraub X; Lepillier A; Chatellier G; Le Heuzey JY;
Am Heart J; 2009 Aug; 158(2):230-237.e1. PubMed ID: 19619699
[TBL] [Abstract][Full Text] [Related]
19. Posttraumatic stress symptoms and predicted mortality in patients with implantable cardioverter-defibrillators: results from the prospective living with an implanted cardioverter-defibrillator study.
Ladwig KH; Baumert J; Marten-Mittag B; Kolb C; Zrenner B; Schmitt C
Arch Gen Psychiatry; 2008 Nov; 65(11):1324-30. PubMed ID: 18981344
[TBL] [Abstract][Full Text] [Related]
20. Predictors of appropriate defibrillator therapy among patients with an implantable defibrillator that delivers cardiac resynchronization therapy.
Desai AD; Burke MC; Hong TE; Kim S; Salem Y; Yong PG; Knight BP
J Cardiovasc Electrophysiol; 2006 May; 17(5):486-90. PubMed ID: 16684019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
